All In Biotech

Drug Trial Radar · NCT06120283

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

433

Planned (sponsor's estimate)

Start

Dec 1, 2023

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Nov 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.

Conditions

  • Advanced Solid Tumor
  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • Hormone-receptor-positive Breast Cancer
  • Hormone Receptor Positive Breast Carcinoma
  • Hormone Receptor Positive Malignant Neoplasm of Breast
  • HER2-negative Breast Cancer
  • Hormone Receptor Positive HER-2 Negative Breast Cancer

Interventions

  • BGB-43395Drug

    Planned doses administered orally.

  • FulvestrantDrug

    Standard dose administered via intramuscular injection.

  • LetrozoleDrug

    Standard dose administered orally as a tablet.

  • ElacestrantDrug

    Standard dose administered orally as a tablet.

  • Anti-Diarrheal AgentDrug

    Administered orally as a tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to approximately 60 months
  2. Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-43395Time frame: Up to approximately 60 months
  3. Phase 1a: Recommended Dose for Expansion (RDFE) of BGB-43395Time frame: Up to approximately 60 months
  4. Phase 1b: Objective Response Rate (ORR)Time frame: Up to approximately 60 months

Locations

61 sites in 11 countries. Site status is shown where the registry gives one.

  • Sarah Cannon Research Institute (Scri) At Health One

    Denver, Colorado · Recruiting

  • Florida Cancer Specialists and Research Institute

    Lake Mary, Florida · Completed

  • Karmanos Cancer Institute

    Detroit, Michigan · Completed

  • Duke Cancer Center

    Durham, North Carolina · Recruiting

  • James Cancer Hospital and Solove Research Institute

    Columbus, Ohio · Recruiting

  • Scri Oncology Partners

    Nashville, Tennessee · Recruiting

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas · Recruiting

  • Next Oncology Dallas

    Irving, Texas · Recruiting

  • Next Oncology

    San Antonio, Texas · Recruiting

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, Australia · Recruiting

  • Southern Highlands Private Hospital

    Bowral, New South Wales, Australia · Recruiting

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia · Recruiting

  • Macquarie University

    North Ryde, New South Wales, Australia · Recruiting

  • Townsville University Hospital

    Douglas, Queensland, Australia · Recruiting

  • Genesiscare St Andrews

    Adelaide, South Australia, Australia · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Completed

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Fundacao Pio Xii Hospital de Amor de Barretos

    Barretos, Brazil · Recruiting

  • Hospital Sirio Libanes Brasilia

    Brasília, Brazil · Recruiting

  • Fundacao Universidade de Caxias Do Sul

    Caxias do Sul, Brazil · Recruiting

  • Centro de Pesquisas Oncologicas Cepon

    Florianópolis, Brazil · Recruiting

  • Liga Norte Riograndene Contra O Cancer

    Natal, Brazil · Recruiting

  • Hospital Sao Lucas Da Pucrs Uniao Brasileira de Educacao E Assistencia

    Porto Algre, Brazil · Recruiting

  • Instituto Nacional de Cancer

    Rio de Janeiro, Brazil · Recruiting

  • Instituto Dor de Pesquisa E Ensino Hospital Sao Rafael

    Salvador, Brazil · Recruiting

  • Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira

    São Paulo, Brazil · Recruiting

  • Clinica de Pesquisa E Centro de Estudos Em Oncologia Ginecologica E Mamaria

    São Paulo, Brazil · Recruiting

  • Hospital Israelita Albert Einstein

    São Paulo, Brazil · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)

    Guangzhou, Guangdong, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • The First Affiliated Hospital of Nanchang University Branch Donghu

    Nanchang, Jiangxi, China · Recruiting

  • Liaoning Cancer Hospital and Institute

    Shenyang, Liaoning, China · Recruiting

  • Fudan University Shanghai Cancer Centerpudong

    Shanghai, Shanghai Municipality, China · Recruiting

  • Centre de Lutte Contre Le Cancer Institut Bergonie

    Bordeaux, France · Recruiting

  • Centre Francois Baclesse

    Caen, France · Recruiting

  • Centre Oscar Lambret

    Lille, France · Recruiting

  • Institut Paoli Calmettes

    Marseille, France · Recruiting

  • Institut Curie

    Paris, France · Recruiting

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.